---
title: "Immuno-oncology Therapeutics: The Next Growth Frontier"
description: By 2050, global cancer incidence will surpass 35 million new cases annually – a 77% surge from 2022
image: https://go.frost.com/hubfs/Images/2025/HLS/GO/PFQN/R01_HLS%20GO%20PFQN%20-%20Medical%20Imaging_072125_VJ_AK3.jpg
---

![Immuno-oncology Therapeutics: The Next Growth Frontier](https://go.frost.com/hs-fs/hubfs/Images/2025/HLS/GO/PFOS/D01_HLS%20GO%20PFOS%20-%20Immuno-oncology_081325_2500x500_VJ_HK.jpg?width=2000&height=400&name=D01_HLS%20GO%20PFOS%20-%20Immuno-oncology_081325_2500x500_VJ_HK.jpg "Immuno-oncology Therapeutics: The Next Growth Frontier")

*Immuno-oncology 2025 & Beyond: Where Innovation Meets Market Leadership*

Industry Imperative

Industry Imperative By 2050, global cancer incidence will surpass 35 million new cases annually – a 77% surge from 2022. The immuno-oncology (I-O) therapeutics market is leading the fight, but challenges in trial design, patient selection, and therapy resistance demand new strategies and disruptive technologies.

[ Instant Access ](https://store.frost.com/growth-opportunities-in-the-immuno-oncology-therapeutics-market-2024-2030.html?utm_source=hs_email&utm_medium=email&utm_term=GL_KM_HLS_GO_PFOS_RD1_Sep25&utm_campaign=HLS02_TG09_PFOS_Aug25)

What This Analysis Covers

Our comprehensive analysis delivers:

- 2025–2030 global I-O revenue streams
- Competitive benchmarking of Merck, Roche, Bristol Myers Squibb, J&J, and more
- Emerging therapeutic categories: CAR-T, TCR, bispecifics, cancer vaccines
- AI-driven clinical trial innovations
- Biomarker advancements: multiplex IHC, NGS, metabolic profiling
- Strategic growth areas: multi-biomarker approaches & neoadjuvant immunotherapy

And more….

### Access the Full Analysis Now

Why This Matters Now

With 88.5% of market revenue controlled by the top 10 players, competition is fierce. The winners will be those who align early with next-gen I-O targets, combination therapies, adaptive trial designs, and global collaboration models to close cancer care disparities.

Gain the intelligence to make high-ROI decisions in one of the most competitive and fast-growing healthcare markets.

### Sign up for a complimentary Growth Pipeline Dialog™

A Growth Pipeline Dialog is a structured discussion with our growth experts providing unparalleled technology intelligence and proven implementation best practices. This discussion will spark innovative thinking and help generate a pipeline of growth opportunities you can leverage to maximize your company’s future growth potential.

Upon completing the dialog session, you will receive a $1,000 honorarium* as a token of our appreciation, which can be used towards the purchase of our products and services on [store.frost.com](https://store.frost.com?utm_source=hslinks).

[ Talk to our experts today! ](https://insights.frost.com/gpdialog?hsCtaTracking=2540db65-be35-44dd-abb4-f667210b0fde%7C973ed019-8950-4e26-8c86-4b58d2df9b85&hsLang=en)

*$1,000 honorarium is subject to eligibility

![drive-growth-image-scaled-2](https://go.frost.com/hs-fs/hubfs/Imported%20sitepage%20images/drive-growth-image-scaled-2.jpg?width=2560&height=1707&name=drive-growth-image-scaled-2.jpg "drive-growth-image-scaled-2")

**